Don't Buy BioMarin Pharmaceutical Inc. (BMRN) Ahead Of ValRox 3-Year Update - Stifel
Tweet Send to a Friend
Stifel analyst Paul Matteis reiterated a Buy rating and $111.00 price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) ahead of ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
